| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥17.9B | ¥16.8B | +7.0% |
| Operating Income | ¥-5.2B | ¥-1.5B | -242.1% |
| Ordinary Income | ¥-5.2B | ¥-1.7B | -203.5% |
| Net Income | ¥-5.2B | ¥-1.9B | -167.1% |
| ROE | -21.5% | -7.9% | - |
FY2025 Q3 cumulative results show revenue of 17.9B yen (YoY +7.0%), while operating loss expanded to -5.2B yen (prior year -1.5B yen, YoY -242.1%), ordinary loss of -5.2B yen (prior -1.7B yen, YoY -203.5%), and net loss of -5.2B yen (prior -1.9B yen, YoY -167.1%). Despite revenue growth, profitability deteriorated significantly with operating margin at -29.0% compared to -9.0% in the prior year. Gross profit margin remained healthy at 51.8%, but SG&A expenses of 14.5B yen (80.8% of revenue) overwhelmed gross profit, resulting in substantial operating losses. All major business segments except Investment posted negative operating income, indicating company-wide profitability challenges.
Revenue increased 1.1B yen YoY to 17.9B yen, representing growth of 7.0%. Segment-level analysis reveals mixed performance: Cosmetics segment revenue grew from 626M yen to 728M yen (+16.3%), while Beauty and Wellness segment declined from 785M yen to 628M yen (-20.0%). Regenerative Medicine Related segment increased from 261M yen to 362M yen (+38.8%). Two new segments emerged during the period: AI Technology (42M yen) and Market Expansion (2M yen), while Investment segment expanded significantly from 2M yen to 30M yen. Despite top-line growth, cost structure deterioration drove profitability decline. Gross profit of 9.3B yen yielded a healthy 51.8% margin, but SG&A expenses of 14.5B yen (representing 80.8% of revenue) resulted in operating loss of -5.2B yen. The gap between gross profit and operating loss widened by approximately 3.7B yen compared to prior year's operating loss of -1.5B yen, indicating substantial fixed cost increases or inefficiencies in operating expense management. Non-operating items showed minimal impact with non-operating income of 0.1B yen and non-operating expenses of 0.1B yen offsetting each other. Extraordinary income of 0.1B yen provided slight cushioning, but was insufficient to materially alter the loss trajectory. The alignment between ordinary loss (-5.2B yen) and net loss (-5.2B yen) indicates no significant tax benefits or extraordinary adjustments, reflecting straightforward loss pass-through. This performance pattern represents revenue up/profit down deterioration, characterized by top-line expansion that failed to translate into profitability improvement due to disproportionate operating expense growth.
Cosmetics segment generated revenue of 728M yen with operating loss of -162M yen (margin -22.2%), representing the largest segment by revenue at 40.6% share, making it the core business. However, profitability deteriorated sharply from prior year's operating loss of -26M yen, with loss expanding by 136M yen despite revenue growth of 102M yen. Beauty and Wellness segment recorded revenue of 628M yen with operating loss of -66M yen (margin -10.5%), a significant deterioration from prior year's operating profit of 32M yen, driven by revenue decline of 157M yen. Regenerative Medicine Related segment achieved revenue of 362M yen with operating loss of -26M yen (margin -6.9%), relatively stable compared to prior year's loss of -26M yen despite revenue growth of 101M yen. Sustainable segment posted minimal revenue of 2M yen with operating loss of -50M yen (margin -2,177.9%), reflecting heavy investment or startup phase with limited revenue generation. Market Expansion segment showed 2M yen revenue with operating loss of -30M yen (margin -1,813.7%), similarly indicating early-stage development. Investment segment delivered the only profitable performance with revenue of 30M yen and operating income of 28M yen (margin 94.3%), expanding significantly from prior year's 2M yen revenue and income. AI Technology segment recorded revenue of 42M yen with operating loss of -99M yen (margin -234.9%), representing substantial investment ahead of revenue realization. Material margin differences exist across segments, with Investment achieving near-breakeven profitability while operational segments suffer double-digit negative margins, highlighting structural profitability challenges in core businesses.
[Profitability] ROE of -21.5% reflects severe earnings deterioration, with operating margin at -29.0% compared to industry median of 8.2% in IT/Telecom sector, indicating substantial underperformance. Net profit margin of -29.0% versus industry median of 6.0% highlights fundamental profitability challenges. Gross profit margin of 51.8% remains healthy, but is completely offset by SG&A ratio of 80.8%. [Cash Quality] Cash and deposits of 1.4B yen provide coverage of 1.4x against short-term loans of 0.95B yen, indicating adequate immediate liquidity. Current ratio of 331.0% and quick ratio of 178.4% demonstrate strong short-term payment capacity, substantially above industry median current ratio of 2.15x. [Investment Efficiency] Asset turnover of 0.51 falls below industry median of 0.67, reflecting lower asset utilization efficiency. Inventory turnover days of 285 days significantly exceeds industry median of 17 days, indicating severe inventory management challenges with potential obsolescence risk. [Financial Health] Equity ratio of 68.6% exceeds industry median of 59.2%, demonstrating conservative capital structure. Debt-to-equity ratio of 0.46x and debt-to-capital ratio of 8.6% indicate low leverage. However, retained earnings of -28.3B yen represent accumulated losses equivalent to 117% of total equity of 24.2B yen, raising concerns about capital erosion. Construction in progress (CIP) of 7.5B yen represents 44.9% of property, plant and equipment, indicating substantial ongoing investments with future depreciation implications.
Cash and deposits decreased from 3.0B yen to 1.4B yen, a decline of 1.6B yen (-53.3% YoY), reflecting significant cash outflow despite revenue growth. Operating losses of -5.2B yen consumed cash, while gross profit generation of 9.3B yen was insufficient to cover SG&A expenses. Working capital movements show mixed signals: inventories increased from 5.4B yen to 6.8B yen (+1.4B yen), suggesting inventory accumulation that ties up cash and aligns with elevated inventory turnover days of 285. Trade receivables increased from 1.9B yen to 2.2B yen (+0.3B yen), consistent with revenue growth but indicating slower collection. Trade payables decreased from 1.8B yen to 1.1B yen (-0.7B yen), suggesting shorter payment cycles or reduced purchasing activity, which released working capital but may indicate constrained supplier credit. Property, plant and equipment increased from 15.4B yen to 16.7B yen (+1.3B yen), with construction in progress rising from 6.2B yen to 7.5B yen (+1.3B yen), indicating continued capital investment despite operating losses. Total assets expanded from 32.5B yen to 35.2B yen (+2.7B yen), driven by fixed asset investments and inventory build. The combination of operating losses, inventory accumulation, and capital investments explains the substantial cash decline. Short-term liabilities of 4.4B yen are well covered by current assets of 14.6B yen, maintaining liquidity cushion of 3.3x. However, the cash burn rate of approximately 1.6B yen over nine months raises sustainability questions if operating losses persist.
Ordinary loss of -5.2B yen closely aligned with operating loss of -5.2B yen indicates minimal non-operating impact, with net non-operating contribution near zero. Non-operating income of 0.1B yen included interest income and other miscellaneous items, while non-operating expenses of 0.1B yen comprised interest expense and other costs, resulting in neutral net effect. Non-operating items represent only 0.6% of revenue, suggesting core operating performance drives overall results without material financial engineering or non-recurring gains. Extraordinary income of 0.1B yen provided slight offset but remains immaterial at 0.6% of revenue. The alignment between operating, ordinary, and net income levels confirms recurring nature of losses, with no significant one-time items masking underlying performance. Without cash flow statement data for the quarterly period, accruals assessment relies on balance sheet movements: the increase in inventories (+1.4B yen) and property, plant and equipment (+1.3B yen) alongside declining cash (-1.6B yen) suggests significant cash outflows for working capital and capital expenditures. While operating cash flow data is unavailable for direct comparison to net income, the cash position decline of 1.6B yen against net loss of 5.2B yen implies some non-cash expenses (depreciation, amortization) partially offset cash consumption, though overall cash generation remains negative. The persistence of operating losses and inventory accumulation raises concerns about earnings sustainability and cash conversion efficiency.
Full-year revenue guidance of 28.4B yen implies 58.8% progress rate through Q3 (17.9B yen actual), which trails the standard 75% expectation for Q3 by 16.2 percentage points, indicating fourth quarter acceleration of 10.5B yen is required to meet guidance. Operating loss guidance of -4.8B yen shows 108.3% progress through Q3 actual loss of -5.2B yen, meaning current losses already exceed full-year guidance by 0.4B yen. This suggests either fourth quarter operational improvement to generate operating profit of approximately 0.4B yen, or potential need for guidance revision. The company noted no forecast revision during the quarter. Progress deviation for revenue indicates fourth quarter must deliver 37.0% of full-year revenue (10.5B yen) compared to Q1-Q3 average of 6.0B yen per quarter, requiring substantial sequential acceleration. Operating loss progression exceeding full-year guidance highlights risk that profitability recovery may take longer than initially forecasted. Forecast assumptions from notes indicate forward-looking statements are based on currently available information and reasonable assumptions, with actual results potentially differing materially. The substantial gap between Q3 operating loss run-rate and full-year guidance target suggests aggressive fourth quarter improvement assumptions built into guidance, warranting close monitoring of expense control measures and revenue acceleration plans.
Annual dividend forecast is 0.00 yen with no interim or year-end dividend planned, maintaining zero payout policy. This represents continuation of no-dividend policy from prior periods. Payout ratio is not calculable given net losses. With net loss of -5.2B yen and negative retained earnings of -28.3B yen, dividend capacity is nonexistent under current earnings structure. The company demonstrates no share buyback activity during the period. Total shareholder return ratio is 0%, reflecting absence of both dividends and buybacks. The zero-dividend policy aligns appropriately with financial condition characterized by operating losses, accumulated deficit, and cash consumption. Restoration of dividend capability requires return to profitability, sustained positive earnings, and rebuilding of retained earnings base. Given the magnitude of accumulated losses and ongoing quarterly losses, dividend resumption appears unlikely in the near term without fundamental operational turnaround and capital structure improvement.
Persistent operating loss expansion across multiple segments. Operating loss widened from -1.5B yen to -5.2B yen YoY despite revenue growth, with only Investment segment achieving profitability. Cosmetics segment loss expanded by 136M yen, Beauty and Wellness swung from 32M yen profit to -66M yen loss, and new segments AI Technology and Market Expansion incurred combined losses of -129M yen. This broad-based profitability deterioration indicates systemic challenges in cost structure and business model execution requiring comprehensive operational restructuring.
Inventory accumulation and working capital inefficiency. Inventory increased 1.4B yen to 6.8B yen (19.2% of total assets) with inventory turnover days of 285 days, dramatically exceeding industry median of 17 days by 268 days. This extreme inventory carrying period raises risks of obsolescence, markdown requirements, and further cash consumption. The inventory build despite only 7.0% revenue growth suggests demand forecasting issues or sales velocity deterioration, potentially requiring write-downs that would further impact profitability.
Refinancing risk from short-term debt concentration. Short-term liabilities represent 41.7% of total liabilities, exceeding typical threshold of 40% and indicating maturity concentration risk. While current ratio of 331.0% provides coverage, the combination of cash decline (-1.6B yen), ongoing operating losses, and accumulated deficit of -28.3B yen may constrain refinancing flexibility. If operating losses persist, lenders may tighten terms or require additional collateral, potentially limiting financial flexibility to fund turnaround initiatives.
[Industry Position] (Reference - Proprietary Analysis)
The company operates in the IT/Telecom sector with diversified business segments including cosmetics, wellness, regenerative medicine, and AI technology. Profitability metrics significantly underperform industry standards: ROE of -21.5% versus industry median of 8.3%, operating margin of -29.0% versus industry median of 8.2%, and net profit margin of -29.0% versus industry median of 6.0%. These gaps exceeding 30-40 percentage points indicate fundamental business model challenges distinct from sector peers. Financial health metrics show relative strength in certain areas: equity ratio of 68.6% exceeds industry median of 59.2%, demonstrating conservative leverage, while current ratio of 331.0% substantially exceeds industry median of 2.15x, indicating strong liquidity position. However, efficiency metrics reveal operational weaknesses: asset turnover of 0.51 trails industry median of 0.67, and inventory turnover days of 285 vastly exceeds industry median of 17 days, highlighting severe working capital management issues. Revenue growth of 7.0% underperforms industry median of 10.4%, suggesting below-average top-line momentum. The company's financial profile reflects early-stage or turnaround characteristics with strong balance sheet foundation (high equity, low leverage) but severe operational execution challenges (negative margins, inventory inefficiency) requiring fundamental business model refinement to converge toward industry profitability norms.
(Industry: IT/Telecom, Comparison: 2025-Q3 period, Source: Proprietary analysis)
Significant profitability deterioration despite revenue growth indicates structural cost challenges requiring operational restructuring. Operating loss expanded 3.7B yen YoY to -5.2B yen even as revenue grew 7.0%, driven by SG&A expenses of 14.5B yen consuming 80.8% of revenue against gross profit margin of 51.8%. This 30-percentage-point gap between gross margin and operating margin highlights excessive fixed cost burden. The broad-based nature of segment losses (six of seven segments unprofitable) suggests company-wide rather than isolated issues, potentially requiring comprehensive review of business unit viability, cost allocation, and operational efficiency initiatives. Near-term focus on SG&A reduction appears critical to restoring path to profitability.
Inventory management and working capital optimization emerge as urgent priorities for cash preservation. Inventory increased 25.9% to 6.8B yen while revenue grew only 7.0%, resulting in inventory turnover days of 285 compared to industry median of 17 days. This extreme divergence suggests either significant obsolescence risk, overstocking of slow-moving products, or channel issues requiring inventory write-downs or aggressive clearance strategies. Combined with cash decline of 1.6B yen and construction in progress of 7.5B yen (44.9% of PP&E), the company faces competing demands for capital deployment. Accelerating inventory conversion to cash through sales initiatives, clearance programs, or supply chain optimization could provide meaningful working capital relief to fund ongoing investments and reduce cash burn rate.
Full-year guidance achievement faces execution risk with fourth quarter requiring substantial improvement. Revenue must accelerate to 10.5B yen in Q4 from 6.0B yen average in Q1-Q3 to meet 28.4B yen guidance, while operating loss guidance of -4.8B yen is already exceeded by Q3 cumulative loss of -5.2B yen. This implies Q4 operating profit of approximately 0.4B yen is necessary, representing dramatic swing from recent quarterly loss run-rate. Achievement would require both revenue acceleration and significant expense reduction materializing simultaneously, suggesting elevated execution risk. Monitoring of monthly operating metrics, cost reduction implementation progress, and potential guidance revision becomes critical for assessing realistic full-year trajectory and management credibility.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.